Of course the mar­ket de­ba­cle will in­flu­ence M&A, deal­mak­ing. The pen­du­lum is swing­ing back to buy­ers

Do you think cer­tain M&A tar­gets look more in­ter­est­ing to you giv­en the sig­nif­i­cant pull­back in biotech val­u­a­tions? Or do you still think some of …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland